7 Common Questions About Ofev

Ofev (nintedanib) is a treatment used for patients with idiopathic pulmonary fibrosis (IPF).  It is an anti-fibrotic drug that was approved by the FDA in October 2014 to help slow down the progression of the disease. Here are some of the most frequently asked questions about Ofev from the manufacturers, Boehringer Ingelheim.

How will Ofev help me?
In patients with a forced vital capacity (FVC) of 50 percent predicted or higher, it slows down the progression of the disease. The drug also works by reducing acute exacerbations of the disease up to 50 percent.

MORE: What you need to know about Ofev

How do I take Ofev?
Ofev comes in capsule form and one 150mg tablet should be taken twice a day with meals. If you experience any side effects, your doctor may reduce your dose to 100mg twice a day. If side effects persist with the lower dosage your doctor may advise you discontinue the medication.

MORE: First PF-ILD patient is enrolled in a Boehringer Ingelheim Phase 3 trial of Ofev therapy.

3 comments

  1. Linda Smith says:

    I was placed on Ofev approximately two years ago. It has worked tremendously well for me. I am no longer on oxygen. It’s like a new life!

  2. Jilly says:

    My husband was diagnosed with IPF on 2nd June 2016, and was put on Ofev, should been reviewed 12th July 2016, Appointment cancelled he was seen on 16th Or 18th August 2016 were it was stopped immediately it certainly didn’t suit him, sadly my husband died 47yr old just 16 weeks 3 days after diagnosis

Leave a Comment

Your email address will not be published. Required fields are marked *